FluoSphera

Overview

FluoSphera is a biotechnology company specializing in advanced in vitro drug discovery solutions. The company has developed a proprietary multi-tissue platform that enables researchers to evaluate drug efficacy and toxicity across multiple human tissues simultaneously, providing a more accurate representation of systemic drug responses. This approach aims to reduce reliance on animal models and improve the predictability of preclinical drug testing. The company's technology utilizes 3D tissue multiplexing to mimic human physiology, allowing for high-throughput screening of drug candidates. FluoSphera's platform is designed to accelerate the drug discovery process by providing earlier insights into systemic effects, thereby enhancing the efficiency and effectiveness of preclinical evaluations. The company collaborates with pharmaceutical companies, contract research organizations (CROs), and biotech innovators worldwide to integrate its technology into drug development pipelines. FluoSphera's commitment to innovation is evident in its recent funding achievements. In January 2026, the company secured €1.23 million (CHF 1.15 million) in a funding round led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New York. The funds are intended to scale commercial collaborations, expand the business development team, and further develop AI and automation capabilities for large-scale imaging analysis. This investment underscores confidence in FluoSphera's cutting-edge solutions and market potential. The company's leadership includes CEO Dr. Clélia Bourgoint, who holds a Ph.D. in Molecular Biology and has implemented advanced microscopy methods for developing new cancer therapies. Co-founder and CSO Gregory Segala has a Ph.D. in Oncology and has identified new targets for breast cancer treatment. The team also includes scientific advisors such as Professor Aurélien Roux, an elected member of the EMBO and a key opinion leader in cell encapsulation technology, and Gerardo Turcatti, Director of the Biomolecular Screening facility at the EPFL in Switzerland. FluoSphera's technology is compatible with high-throughput screening workflows and is already used by biotech and pharmaceutical companies, particularly for antibody-drug conjugate testing. The company aims to broaden access to advanced human tissue modeling and bring precision medicine closer to reality by tailoring drug testing to different population subgroups. With a focus on reducing preclinical expenditure and improving drug discovery outcomes, FluoSphera continues to advance its mission of making drug discovery faster, safer, and more human-relevant. FluoSphera's technology is compatible with high-throughput screening workflows and is already used by biotech and pharmaceutical companies, particularly for antibody-drug conjugate testing. The company aims to broaden access to advanced human tissue modeling and bring precision medicine closer to reality by tailoring drug testing to different population subgroups. With a focus on reducing preclinical expenditure and improving drug discovery outcomes, FluoSphera continues to advance its mission of making drug discovery faster, safer, and more human-relevant.

Investment Focus

• Innovative drug discovery technologies
• Advanced in vitro testing platforms
• High-throughput screening capabilities
• AI and automation in drug discovery
• Reduction of animal testing in preclinical studies
• Human-relevant preclinical models
• Collaborations with pharmaceutical companies
• Integration into drug development pipelines
• Expansion into international markets
• Scalable business development strategies
• Advanced imaging analysis capabilities
• Preclinical testing solutions
• Clinical trial preparation
• Regulatory compliance in drug testing
• Research and development in biotechnology
• Medical research advancements
• Health technology innovations
• Biotech startup growth
• Pharmaceutical industry partnerships
• Contract research organization collaborations

Portfolio Companies